It’s true that we’ve come a long way in recent years when it comes to treating multiple myeloma. More therapies are being developed, to the point where somebody diagnosed now is likely to have ...

About 6,000 people in the UK are diagnosed with multiple myeloma each year. The new time-saving test is intended for people with MGUS (Monoclonal Gammopathy of Unknown Significance), a precursor ...

BUFFALO, N.Y. (WKBW) — March is Multiple Myeloma Awareness Month, a time to shed light on this rare form of blood cancer and those who battle it every day. For Buffalo attorney and Niagara ...

Blocking the chemokine receptor CCR1 can enhance the response of multiple myeloma cells to dexamethasone, a common treatment. High CCR1 levels are associated with poor outcomes and glucocorticoid ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in ...

It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK's first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio's ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in ...

The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or -deferred multiple myeloma. The regimen reduced risk for disease progression or death by 43%.

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed ...